COMMUNIQUÉS West-GlobeNewswire

Metsera Reports Fourth Quarter and Full Year 2024 Financial Results and Continued Portfolio Progress
26/03/2025
MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, is being studied in multiple Phase 2b clinical trials with read-outs beginning mid-2025 Multiple data readouts in mid and late 2025 on track [...]
Nanox to Present New Data Featuring AI Bone Solution at Four Medical Conferences through June 2025 across Europe
26/03/2025
ADOPT Study Findings Highlight Nanox.AI’s Role in Enhancing Fracture Detection and Healthcare Cost Savings PETACH TIKVA, Israel, March 26, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ("Nanox" or the "Company", Nasdaq: [...]
Financière de Tubize - Convening of the ordinary and extraordinary general meetings of shareholders of April 25, 2025
26/03/2025
Convening of the Ordinary and Extraordinary General Meetings of shareholders of 25 April 2025 The shareholders are invited to attend the ordinary and extraordinary general meetings, which will take place on Friday 25th [...]
Financière de Tubize - Convocation aux assemblées générales ordinaire et extraordinaire du 25/04/2025
26/03/2025
Convocation des actionnaires à l’Assemblée Générale Ordinaire et à l’Assemblée Générale Extraordinaire du 25 avril 2025 Les actionnaires sont invités à prendre part à l’assemblée générale ordinaire et à l’assemblée [...]
Avacta Therapeutics Announces Presentations at 2025 AACR Annual Meeting
26/03/2025
LONDON and PHILADELPHIA, March 26, 2025 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads [...]
Microbix Further Optimizes Capital Usage and Availability
26/03/2025
Debt Repayment & Credit Expansion Provides Savings & Maintains Resilience MISSISSAUGA, Ontario, March 26, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. ( TSX: MBX, OTCQX: MBXBF, Microbix ® ), a life sciences [...]
Hair Loss Hero: 2DDR HEALTHCARE Shares Results From Customer Driven Hair Loss Research Study
26/03/2025
2DDR HEALTHCARE, LLC reveals promising hair growth results with new serum, evidencing new hair growth within 6-12 weeks. Dover, Delaware, March 26, 2025 (GLOBE NEWSWIRE) -- 2DDR HEALTHCARE, LLC, a biosciences company [...]
Verrica Pharmaceuticals Appoints Noah L. Rosenberg, M.D., as Chief Medical Officer
26/03/2025
WEST CHESTER, Pa., March 26, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring [...]
Zymeworks Announces Participation in Upcoming Investor Conferences
26/03/2025
VANCOUVER, British Columbia, March 26, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve [...]
UK Medicines and Healthcare Products Regulatory Agency Confirms Acceptance of Marketing Authorization Application for Proposed Biosimilar to Xolair® (omalizumab)
26/03/2025
REYKJAVIK, Iceland, PISCATAWAY, N.J. and LONDON, March 26, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacturing of biosimilar medicines for [...]
UK Medicines and Healthcare Products Regulatory Agency Confirms Acceptance of Marketing Authorization Application for Proposed Biosimilar to Xolair® (omalizumab)
26/03/2025
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacturing of biosimilar medicines for patients worldwide, Kashiv Biosciences LLC (“Kashiv”), a fully integrated biopharmaceutical [...]
FDA Issues Nyxoah an Approvable Letter for its Genio® System
26/03/2025
INSIDE INFORMATION REGULATED INFORMATION FDA Issues Nyxoah an Approvable Letter for its Genio® System Mont-Saint-Guibert, Belgium – March 26, 2025, 8:00am CET / 3:00am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“ [...]
La FDA Délivre à Nyxoah une Lettre d'Approuvabilité pour son système Genio®
26/03/2025
INFORMATIONS PRIVILÉGIÉES INFORMATIONS RÉGLEMENTÉES La FDA Délivre à Nyxoah une Lettre d'Approuvabilité pour son Système Genio® Mont-Saint-Guibert, Belgique – 26 mars 2025, 8h00 CET / 3h00 ET – Nyxoah SA (Euronext [...]
Pleco Therapeutics Announces Positive Outcome of Pre-IND meeting with FDA for PTX-252 in Acute Myeloid Leukaemia
26/03/2025
NIJMEGEN, The Netherlands, March 26, 2025 (GLOBE NEWSWIRE) -- Pleco Therapeutics, a clinical-stage biopharmaceutical company developing novel therapies for difficult-to-treat cancers, announces a positive outcome from [...]
ONWARD Medical Announces First-in-Human Use of ARC-IM Lumbar Lead Designed to Restore Standing, Stepping, and Lower Limb Mobility
26/03/2025
The ARC-IM Lumbar Lead is the second model in the ARC-IM Lead family to be used in a clinical feasibility study The Company is building a portfolio of purpose-designed leads to optimize delivery of ARC-IM Therapy at [...]
Press Release: Chlamydia vaccine candidate granted fast track designation by the US FDA
26/03/2025
Chlamydia vaccine candidate granted fast track designation by the US FDA Chlamydia infection can contribute to pelvic inflammatory diseases in women, which can lead to pregnancy complications or infertility A phase 1/2 [...]
Communiqué de presse : La FDA des États-Unis accorde une procédure accélérée au candidat-vaccin contre les infections à Chlamydia
26/03/2025
La FDA des États-Unis accorde une procédure accélérée au candidat-vaccin contre les infections à Chlamydia Les infections à Chlamydia peuvent contribuer à l’apparition d’inflammations pelviennes chez la femme et être à [...]
BioVersys Reports Corporate Highlights and Key Financials for the Full Year 2024
26/03/2025
BASEL, Switzerland, March 26, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR BV100: Positive Phase 2 VABP trial read-out with excellent safety and efficacy data Alpibectir: Phase 2a EBA trial [...]
Humacyte, Inc. Announces Pricing of Public Offering of Common Stock
26/03/2025
DURHAM, N.C., March 25, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, [...]

Pages